365 related articles for article (PubMed ID: 20810669)
1. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
2. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Hosono K; Endo H; Takahashi H; Sugiyama M; Uchiyama T; Suzuki K; Nozaki Y; Yoneda K; Fujita K; Yoneda M; Inamori M; Tomatsu A; Chihara T; Shimpo K; Nakagama H; Nakajima A
Mol Carcinog; 2010 Jul; 49(7):662-71. PubMed ID: 20564343
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Oct; 20(1):1043. PubMed ID: 33121471
[TBL] [Abstract][Full Text] [Related]
4. Colon epithelial proliferation and carcinogenesis in diet-induced obesity.
Takahashi H; Hosono K; Endo H; Nakajima A
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():41-7. PubMed ID: 24251703
[TBL] [Abstract][Full Text] [Related]
5. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
6. Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence.
Uchiyama T; Takahashi H; Endo H; Kato S; Sakai E; Hosono K; Yoneda M; Inamori M; Hippo Y; Nakagama H; Nakajima A
Dig Endosc; 2012 Sep; 24(5):353-7. PubMed ID: 22925289
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm.
Sakai E; Takahashi H; Kato S; Uchiyama T; Hosono K; Endo H; Maeda S; Yoneda M; Taguri M; Nakajima A
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1918-24. PubMed ID: 21750169
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Aug; 20(1):770. PubMed ID: 32807113
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of colorectal cancer.
Niitsu Y; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Abe T; Kogawa T; Takahashi M; Matsunaga T; Kato J
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S40-3. PubMed ID: 15309513
[TBL] [Abstract][Full Text] [Related]
10. Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.
Anderson JC; Swede H; Rustagi T; Protiva P; Pleau D; Brenner BM; Rajan TV; Heinen CD; Levine JB; Rosenberg DW
Cancer Causes Control; 2012 Feb; 23(2):355-61. PubMed ID: 22187142
[TBL] [Abstract][Full Text] [Related]
11. Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer.
Ohkubo H; Takahashi H; Yamada E; Sakai E; Higurashi T; Uchiyama T; Hosono K; Endo H; Taguri M; Nakajima A
Oncol Rep; 2012 May; 27(5):1475-80. PubMed ID: 22246586
[TBL] [Abstract][Full Text] [Related]
12. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
[TBL] [Abstract][Full Text] [Related]
13. Histomorphology of aberrant crypt foci in colorectal carcinoma.
Norlida AO; Phang KS
Malays J Pathol; 2010 Dec; 32(2):111-6. PubMed ID: 21329182
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans.
Rudolph RE; Dominitz JA; Lampe JW; Levy L; Qu P; Li SS; Lampe PD; Bronner MP; Potter JD
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):605-8. PubMed ID: 15767337
[TBL] [Abstract][Full Text] [Related]
15. Aberrant crypt foci: what we know and what we need to know.
Gupta AK; Pretlow TP; Schoen RE
Clin Gastroenterol Hepatol; 2007 May; 5(5):526-33. PubMed ID: 17433788
[TBL] [Abstract][Full Text] [Related]
16. Suppressive effect of RAS inhibitor manumycin A on aberrant crypt foci formation in the azoxymethane-induced rat colorectal carcinogenesis model.
Tsuda M; Okamoto K; Muguruma N; Sannomiya K; Nakagawa T; Miyamoto H; Kitamura S; Goji T; Kimura T; Okahisa T; Izumi K; Takayama T
J Gastroenterol Hepatol; 2013 Oct; 28(10):1616-23. PubMed ID: 23730936
[TBL] [Abstract][Full Text] [Related]
17. Rectal mucosal proliferation and risk of colorectal adenomas: results from a randomized controlled trial.
Sandler RS; Baron JA; Tosteson TD; Mandel JS; Haile RW
Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):653-6. PubMed ID: 10919733
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
19. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
[No Abstract] [Full Text] [Related]
20. Association of visceral fat accumulation and plasma adiponectin with rectal dysplastic aberrant crypt foci in a clinical population.
Takahashi H; Takayama T; Yoneda K; Endo H; Iida H; Sugiyama M; Fujita K; Yoneda M; Inamori M; Abe Y; Saito S; Wada K; Nakagama H; Nakajima A
Cancer Sci; 2009 Jan; 100(1):29-32. PubMed ID: 19018760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
